Skip to content

Prospective observation on prevention and treatment of diarrhea in patients with HR+/HER2- breast cancer caused by Abemaciclib with Yigong Powder

Prospective observation on prevention and treatment of diarrhea in patients with HR+/HER2- breast cancer caused by Abemaciclib with Yigong Powder

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081155
Enrollment
Unknown
Registered
2024-02-23
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Observation group:On the basis of standard Abemaciclib combined with endocrine therapy, Yigong Powder decoction was used, which consisted of Radix Codonopsis 10g, Poria 10g, Radix Glycyrrhizae 10g, At
Control group:Only standard Abemaciclib combined with endocrine therapy was used.

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Women (regardless of menopause), ? Age =18 years old ? It was diagnosed as HR+, HER2- and invasive breast cancer by pathology, and there was no evidence of distant metastasis. (According to the requirement of HR+ disease, the tumor must be ER or PR positive as determined by immunohistochemistry (IHC). ) ? Received definite surgery for primary breast tumor. ? Meet the diagnostic criteria of postoperative high-risk breast cancer. ? Patients were subsequently treated with Abemaciclib combined with endocrine therapy (the endocrine therapy was AI or AI+OFS); ? Patients have certain knowledge and understanding ability, can understand, and voluntarily participate in the experiment and sign the informed consent form.

Exclusion criteria

Exclusion criteria: ? Patients with gastrointestinal related diseases, or patients who are prone to diarrhea. ? Combined with other primary malignant tumors; ? Complicated with organic cardiovascular and cerebrovascular diseases, or serious diseases of respiratory system, digestive system, nervous system, urinary system, blood system and endocrine system, and severe mental illness;

Design outcomes

Primary

MeasureTime frame
Frequency and duration of diarrhea with grade =2;

Secondary

MeasureTime frame
Medication status of Abemaciclib;Medication status of Loperamide;FACIT-D(Version4);Frequency and duration of diarrhea at all levels;Frequency of vomiting;The frequency of nausea;Frequency of constipation;Traditional Chinese medicine symptom score;Functional Assessment of Cancer Therapy–Breast ( FACT-B);The Functional Assessment of Cancer Therapy–Endocrine Symptoms (FACT-ES);Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT-Fatigue);Adverse Events, AE;

Countries

China

Contacts

Public ContactBinxu Sun

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

sunbinxu@126.com+86 139 2063 7796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026